Corcept Therapeutics Reports Q4 2025 Earnings Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CORT?
Source: seekingalpha
- Revenue Growth: Corcept Therapeutics reported a revenue of $761 million for 2025, marking a 13% increase from $675 million in 2024, with expectations for 2026 revenue to rise to between $900 million and $1 billion, indicating strong demand and growth potential in the Cushing's syndrome market.
- Net Income Decline: The net income for 2025 was $99.7 million, down 29% from $141.2 million the previous year, reflecting financial pressure amid the FDA's rejection of relacorilant, yet management remains optimistic about future market prospects.
- Record Demand for Medications: The number of new prescriptions reached a record high in 2025, increasing by 61% compared to 2024, although tablet sales only grew by 37%, highlighting challenges in the company's supply chain while demonstrating significant market acceptance of new drugs.
- Legal Risks and Responses: The company plans to appeal the court ruling against Teva Pharmaceuticals and will meet with the FDA in April to clarify its position on relacorilant, showcasing proactive strategies in addressing legal and regulatory challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 35.340
Low
50.00
Averages
91.00
High
121.00
Current: 35.340
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corcept Therapeutics Reports Q4 2025 Earnings Highlights
- Revenue Growth: Corcept Therapeutics reported a revenue of $761 million for 2025, marking a 13% increase from $675 million in 2024, with expectations for 2026 revenue to rise to between $900 million and $1 billion, indicating strong demand and growth potential in the Cushing's syndrome market.
- Net Income Decline: The net income for 2025 was $99.7 million, down 29% from $141.2 million the previous year, reflecting financial pressure amid the FDA's rejection of relacorilant, yet management remains optimistic about future market prospects.
- Record Demand for Medications: The number of new prescriptions reached a record high in 2025, increasing by 61% compared to 2024, although tablet sales only grew by 37%, highlighting challenges in the company's supply chain while demonstrating significant market acceptance of new drugs.
- Legal Risks and Responses: The company plans to appeal the court ruling against Teva Pharmaceuticals and will meet with the FDA in April to clarify its position on relacorilant, showcasing proactive strategies in addressing legal and regulatory challenges.
See More
Corcept Therapeutics Accused of Misleading Investors in Class Action
- Lawsuit Background: Robbins LLP has alerted investors about a class action filed on behalf of shareholders who purchased Corcept Therapeutics (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, alleging the company misled investors regarding its new drug application process.
- Product Candidate: Corcept's lead product candidate, relacorilant, is being developed to treat hypercortisolism (Cushing's syndrome), but the company's claims of “powerful support” from clinical trials starkly contrast with the FDA's actual feedback regarding the NDA.
- FDA Response: On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter (CRL) for the NDA of relacorilant, requiring additional evidence of effectiveness, which caused the stock price to plummet from $70.20 to $34.80, a decline of 50.4%.
- Investor Impact: This stock price drop not only highlights the risks associated with the FDA's review of relacorilant but also exposes investors to significant losses, prompting Robbins LLP to seek representation for shareholders in pursuit of compensation.
See More
Corcept Therapeutics Q4 Earnings Miss Expectations
- Disappointing Earnings: Corcept Therapeutics reported a Q4 GAAP EPS of $0.20, missing expectations by $0.07, indicating pressure on profitability that could undermine investor confidence.
- Weak Revenue Growth: The company generated $202.1 million in revenue for Q4, an 11.2% year-over-year increase, yet fell short of the $254.84 million forecast, suggesting sales growth did not meet analyst expectations, potentially leading to downward revisions in future guidance.
- Negative Market Reaction: The market remains cautious due to Relacorilant's failure to secure FDA approval, which may put pressure on the stock price, prompting investors to closely monitor the performance of subsequent product lines.
- Increased Competitive Pressure: With the emergence of generics, Korlym faces heightened market competition; although it has shown strength in certain areas, the changing market landscape could impact the company's long-term growth potential.
See More
Corcept Faces Lawsuit for Ignoring FDA Warnings; Stock Plummets 50%
- Lawsuit Background: Hagens Berman has filed a securities class action against Corcept Therapeutics, alleging that the company misled investors between October 2024 and December 2025, resulting in a 50% stock plunge following FDA warning disclosures.
- FDA Warnings: The lawsuit claims that while Corcept asserted its lead product relacorilant was backed by 'powerful evidence' and 'approaching approval,' the FDA had warned them multiple times about inadequate clinical data, which management allegedly ignored.
- Investor Losses: Investors are urged to apply as Lead Plaintiff by April 21, 2026, to seek compensation for significant losses incurred due to misleading statements, highlighting the urgency of the legal action.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to consider the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, further underscoring the legal risks and potential financial implications facing the company.
See More
Class Action Lawsuit Announced for Corcept Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Corcept Therapeutics (NASDAQ:CORT) for stock purchasers between October 31, 2024, and December 30, 2025, indicating potential compensation risks for investors.
- Legal Procedure Requirements: Investors wishing to serve as lead plaintiffs must file with the court by April 21, 2026, highlighting the urgency of legal proceedings and the necessity for investor participation.
- Compensation Mechanism Explained: Investors joining the class action may receive compensation without any upfront costs, making this no-risk compensation arrangement appealing to a broader range of investors.
- Lawsuit Background Revealed: The lawsuit alleges that Corcept misrepresented clinical trial data supporting the NDA for relacorilant, leading to investor losses upon the revelation of the true circumstances, showcasing significant deficiencies in the company's information disclosure practices.
See More
Corcept Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by April 21, 2026, to participate in the securities class action against Corcept, which involves stock purchases made between October 31, 2024, and December 30, 2025, highlighting investor concerns over the company's disclosure practices.
- Allegations Overview: Corcept and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, particularly regarding the likelihood of FDA approval for their new drug application, indicating a lack of transparency from the company.
- Stock Price Plunge: Following the FDA's issuance of a Complete Response Letter on December 31, 2025, Corcept's stock price plummeted by $35.40, or 50.4%, from $70.20 on December 30, 2025, to $34.80, severely impacting investor confidence and market perception.
- Legal Consultation Opportunity: Investors can contact KSF law firm to discuss their legal rights and how to participate in the lawsuit, demonstrating the firm's commitment to supporting investors in recovering economic losses due to corporate misconduct.
See More
Corcept Therapeutics Reports Q4 2025 Earnings Highlights
- Revenue Growth: Corcept Therapeutics reported a revenue of $761 million for 2025, marking a 13% increase from $675 million in 2024, with expectations for 2026 revenue to rise to between $900 million and $1 billion, indicating strong demand and growth potential in the Cushing's syndrome market.
- Net Income Decline: The net income for 2025 was $99.7 million, down 29% from $141.2 million the previous year, reflecting financial pressure amid the FDA's rejection of relacorilant, yet management remains optimistic about future market prospects.
- Record Demand for Medications: The number of new prescriptions reached a record high in 2025, increasing by 61% compared to 2024, although tablet sales only grew by 37%, highlighting challenges in the company's supply chain while demonstrating significant market acceptance of new drugs.
- Legal Risks and Responses: The company plans to appeal the court ruling against Teva Pharmaceuticals and will meet with the FDA in April to clarify its position on relacorilant, showcasing proactive strategies in addressing legal and regulatory challenges.
See More
Corcept Therapeutics Accused of Misleading Investors in Class Action
- Lawsuit Background: Robbins LLP has alerted investors about a class action filed on behalf of shareholders who purchased Corcept Therapeutics (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, alleging the company misled investors regarding its new drug application process.
- Product Candidate: Corcept's lead product candidate, relacorilant, is being developed to treat hypercortisolism (Cushing's syndrome), but the company's claims of “powerful support” from clinical trials starkly contrast with the FDA's actual feedback regarding the NDA.
- FDA Response: On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter (CRL) for the NDA of relacorilant, requiring additional evidence of effectiveness, which caused the stock price to plummet from $70.20 to $34.80, a decline of 50.4%.
- Investor Impact: This stock price drop not only highlights the risks associated with the FDA's review of relacorilant but also exposes investors to significant losses, prompting Robbins LLP to seek representation for shareholders in pursuit of compensation.
See More
Corcept Therapeutics Q4 Earnings Miss Expectations
- Disappointing Earnings: Corcept Therapeutics reported a Q4 GAAP EPS of $0.20, missing expectations by $0.07, indicating pressure on profitability that could undermine investor confidence.
- Weak Revenue Growth: The company generated $202.1 million in revenue for Q4, an 11.2% year-over-year increase, yet fell short of the $254.84 million forecast, suggesting sales growth did not meet analyst expectations, potentially leading to downward revisions in future guidance.
- Negative Market Reaction: The market remains cautious due to Relacorilant's failure to secure FDA approval, which may put pressure on the stock price, prompting investors to closely monitor the performance of subsequent product lines.
- Increased Competitive Pressure: With the emergence of generics, Korlym faces heightened market competition; although it has shown strength in certain areas, the changing market landscape could impact the company's long-term growth potential.
See More
Corcept Faces Lawsuit for Ignoring FDA Warnings; Stock Plummets 50%
- Lawsuit Background: Hagens Berman has filed a securities class action against Corcept Therapeutics, alleging that the company misled investors between October 2024 and December 2025, resulting in a 50% stock plunge following FDA warning disclosures.
- FDA Warnings: The lawsuit claims that while Corcept asserted its lead product relacorilant was backed by 'powerful evidence' and 'approaching approval,' the FDA had warned them multiple times about inadequate clinical data, which management allegedly ignored.
- Investor Losses: Investors are urged to apply as Lead Plaintiff by April 21, 2026, to seek compensation for significant losses incurred due to misleading statements, highlighting the urgency of the legal action.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to consider the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, further underscoring the legal risks and potential financial implications facing the company.
See More
Class Action Lawsuit Announced for Corcept Therapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit against Corcept Therapeutics (NASDAQ:CORT) for stock purchasers between October 31, 2024, and December 30, 2025, indicating potential compensation risks for investors.
- Legal Procedure Requirements: Investors wishing to serve as lead plaintiffs must file with the court by April 21, 2026, highlighting the urgency of legal proceedings and the necessity for investor participation.
- Compensation Mechanism Explained: Investors joining the class action may receive compensation without any upfront costs, making this no-risk compensation arrangement appealing to a broader range of investors.
- Lawsuit Background Revealed: The lawsuit alleges that Corcept misrepresented clinical trial data supporting the NDA for relacorilant, leading to investor losses upon the revelation of the true circumstances, showcasing significant deficiencies in the company's information disclosure practices.
See More
Corcept Therapeutics Faces Securities Class Action Lawsuit
- Lawsuit Deadline: Investors must file lead plaintiff applications by April 21, 2026, to participate in the securities class action against Corcept, which involves stock purchases made between October 31, 2024, and December 30, 2025, highlighting investor concerns over the company's disclosure practices.
- Allegations Overview: Corcept and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, particularly regarding the likelihood of FDA approval for their new drug application, indicating a lack of transparency from the company.
- Stock Price Plunge: Following the FDA's issuance of a Complete Response Letter on December 31, 2025, Corcept's stock price plummeted by $35.40, or 50.4%, from $70.20 on December 30, 2025, to $34.80, severely impacting investor confidence and market perception.
- Legal Consultation Opportunity: Investors can contact KSF law firm to discuss their legal rights and how to participate in the lawsuit, demonstrating the firm's commitment to supporting investors in recovering economic losses due to corporate misconduct.
See More
